

1 Impact of community treatment with ivermectin for the control of scabies on the  
2 prevalence of antibodies to *Strongyloides stercoralis* in children

3

4 Michael Marks<sup>1,2</sup>, Sarah Gwyn<sup>3</sup>, Hilary Toloka<sup>4</sup>, Christian Kositz<sup>1</sup>, James  
5 Asugeni<sup>4</sup>, Rowena Asugeni<sup>4</sup>, Jason Diau<sup>4</sup>, John M Kaldor<sup>5</sup>, Lucia Romani<sup>5</sup>, Michelle  
6 Redman-MacLaren<sup>6</sup>, David MacLaren<sup>6</sup>, Anthony W Solomon<sup>1,2</sup>, David CW Mabey<sup>1</sup>.

7 <sup>2</sup> Andrew C Steer<sup>7,8,9</sup>, Diana Martin<sup>3</sup>

8

9 1 Clinical Research Department, Faculty of Infectious and Tropical Diseases,  
10 London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E  
11 7HT, United Kingdom

12

13 2 Hospital for Tropical Diseases, University College London Hospitals NHS Trust,  
14 London, WC1E 6JB, United Kingdom

15

16 3 Division of Parasitic Diseases and Malaria, Centers for Disease Control and  
17 Prevention, Atlanta, United States of America

18

19 4 Atoifi Adventist Hospital, Atoifi, Malaita Province, Solomon Islands

20

21 5 Kirby Institute, University of New South Wales, Sydney, Australia

22

23 6 College of Medicine and Dentistry, James Cook University, Cairns, Queensland,  
24 Australia

25

26 7 Department of Paediatrics, University of Melbourne, Melbourne, Victoria,  
27 Australia

28

29 8 Department of General Medicine, Royal Children's Hospital, Melbourne,  
30 Victoria, Australia

31

32 9 Tropical Diseases Research Group, Murdoch Children's Research Institute,  
33 Melbourne, Victoria, Australia

34

35 **Author for Correspondence:**

36 Michael Marks

37 Clinical Research Department,

38 Faculty of Infectious and Tropical Diseases,

39 London School of Hygiene & Tropical Medicine,

40 Keppel Street,

41 London, WC1E 7HT

42 United Kingdom

43 [michael.marks@lshtm.ac.uk](mailto:michael.marks@lshtm.ac.uk)

44

45 **Running Title:**

46 Ivermectin MDA and Strongyloides

47

48 **Key Words:**

49 Scabies

50 Neglected tropical diseases

51 Ivermectin

52 Strongyloides

53

54

55

56

57

58 **Abstract**

59

60 Prevalence of antibodies to *Strongyloides stercoralis* was measured in 0–12-year-  
61 olds using a bead-based immunoassay before and after ivermectin mass drug  
62 administration (MDA) for scabies in the Solomon Islands. Seroprevalence was  
63 9.3% before and 5.1% after MDA ( $p = 0.019$ ), demonstrating collateral benefits  
64 of scabies MDA in this setting.

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91 **Introduction:**

92 *Strongyloides stercoralis*, is unique among soil-transmitted helminths (STHs) in  
93 its ability to complete its life cycle within the human host. *S. stercoralis* infection  
94 is most commonly asymptomatic but may be associated with eosinophilia,  
95 fatigue, diarrhoea and occasionally larva currens [1]. People with compromised  
96 immune systems are at risk of potentially fatal hyperinfection syndrome [1].  
97 Albendazole or mebendazole are effective against other major STH species and  
98 have been incorporated into mass drug administration (MDA) programs for  
99 public health purposes. However, these drugs have limited efficacy for  
100 strongyloidiasis, for which ivermectin is the first-line agent.

101 MDA with ivermectin is used widely to control a number of neglected tropical  
102 diseases (NTDs), including lymphatic filariasis, onchocerciasis and, most  
103 recently, scabies [2,3], but has so far not been adopted for *S. stercoralis* control.  
104 Given the drug's broad anti-parasitic effect, MDA with ivermectin may have as a  
105 collateral benefit the population-level control of *S. stercoralis*. Evaluation of *S.*  
106 *stercoralis* control has been facilitated by serological assays that detect  
107 antibodies against the NIE antigen, which is present in infective L3 larvae [4]  
108 These antibodies likely indicate current or recent infection [5] and have high  
109 sensitivity and specificity compared to stool examination[4]. The NIE antigen has  
110 been adapted for use in the Luminex platform, allowing large scale screening of  
111 populations using dried blood spots [6].

112

113 In the context of a community-randomized trial evaluating the addition of  
114 azithromycin to ivermectin-based MDA for scabies and impetigo in the Solomon  
115 Islands, we measured the prevalence of antibody responses to the *S. stercoralis*  
116 NIE antigen before and after MDA.

117

118 **Methods:**

119 The trial of MDA for scabies and impetigo has been described elsewhere [7].  
120 Briefly, selected communities in Malaita province in the Solomon Islands were  
121 randomised to MDA with open label ivermectin or ivermectin plus azithromycin.  
122 All residents of these communities were eligible to participate. In both trial arms,

123 all participants were examined for scabies and offered a single oral dose of  
124 ivermectin (200 µg/kg of body weight). People with a contraindication to  
125 ivermectin (pregnancy, breast-feeding, or weight <15 kg) were offered topical  
126 permethrin instead. Those in whom a clinical diagnosis of scabies was made at  
127 baseline were given a second dose of ivermectin 7–14 days later. Written  
128 informed consent was obtained from adults and from a parent or guardian of  
129 each child aged under 18 years. Assent was also obtained from children who  
130 were able to provide it. The study was approved by the London School of  
131 Hygiene & Tropical Medicine Ethics Committee, the Solomon Islands National  
132 Health Ethics Committee and the Atoifi Adventist Hospital Ethics Committee. The  
133 main trial was prospectively registered on [clinicaltrials.gov](https://clinicaltrials.gov) (NCT02775617).  
134 CDC staff did not interact with study participants or have access to identifying  
135 information.

136

137 For the sub-study reported here, we collected dried-blood spots (DBS) from all  
138 children aged less than 13 years at the baseline and 12-month surveys. We used  
139 a fluorescent bead-based assay to test for antibodies against the recombinant  
140 NIE antigen [6]. Briefly, serum was incubated with microspheres conjugated to  
141 NIE, beads were washed to remove unbound immunoglobulin (Ig), and then  
142 bound anti-NIE antibody was detected using biotinylated anti-human IgG+IgG4  
143 antibody followed by streptavidin-phycoerythrin. Plates were run on a Luminex-  
144 200 (Austin, TX USA) and results reported as median fluorescence intensity with  
145 background subtracted. We used a receiver operating characteristic curve  
146 analysis to determine cut-offs for seropositivity.

147

148 We conducted a before and after analysis to determine the effect of the MDA on  
149 prevalence of antibodies to *S. stercoralis*. Azithromycin has no known activity  
150 against *S. stercoralis* so we combined the two trial arms into a single group for  
151 analysis. We calculated the seroprevalence of *S. stercoralis* at baseline and twelve  
152 months, and the absolute and relative reduction at twelve months, along with  
153 associated confidence intervals and statistical tests of significance. Statistical  
154 analysis was conducted in R 3.4.2 (Vienna, Austria).

155

156

157

158 **Results:**

159 In total, 1,291 people, including 553 0–12-year-olds were recruited and offered  
160 treatment for scabies at the time of the baseline survey. We collected DBS from  
161 539 of these children, representing more than 97% of children enrolled in the  
162 trial. At the 12-month follow-up, 1,085 individuals (including 479 0–12-year-  
163 olds) were seen, and we collected DBS from 448 children (94%). At baseline,  
164 9.3% of the children were seropositive for antibodies to NIE, with a range across  
165 the six study communities of 2.2% to 14.3% (Table 1). At the 12-month follow-  
166 up, the overall prevalence had declined to 5.1% with a range across the  
167 communities of 2.1% to 6.7%. The absolute difference in prevalence between  
168 baseline and 1 year was 4.2% (95% CI 0.7–7.5%) and the relative reduction was  
169 45% ( $p = 0.019$ ) The seroprevalence of antibodies to NIE was lower at the  
170 follow-up visit than at baseline in all communities (Table). Neither the baseline  
171 seroprevalence nor the magnitude of change following MDA was higher in  
172 communities with a higher baseline prevalence of scabies where more  
173 individuals would have received two doses of ivermectin at baseline (Table).

174

175 **Discussion:**

176 Our study adds to the limited available data on the impact of ivermectin MDA on  
177 *S. stercoralis* prevalence. In the Northern Territory of Australia, a single round of  
178 MDA with ivermectin reduced *S. stercoralis* seroprevalence from 21% at baseline  
179 to 5% at 6 months, and a second MDA at month 12 further reduced the  
180 seroprevalence to 2% at month 18 [8]. In Ecuador, the prevalence of *S. stercoralis*  
181 fell from 6.8% to zero following multiple rounds of MDA conducted for the  
182 purpose of onchocerciasis elimination[9]. We showed that in 6 communities in  
183 Malaita, Solomon Islands, there was a decrease in seroprevalence of anti-NIE  
184 antibodies one year after a single ivermectin MDA conducted for the purpose of  
185 scabies control.

186

187 In the absence of a gold standard test for diagnosis of *S. stercoralis*, we used  
188 serological markers that correlate well with more direct measures of infection.

189 Had we combined serology with other tests such as Kato-Katz or PCR on stool  
190 specimens, we may have detected more cases. We were, however, consistent in  
191 the measurement of exposure at both time points so are confident in the relative  
192 change observed. As complete seroreversion of anti-NIE responses after  
193 treatment may take more than one year[5], and it is not clear that all anti-NIE  
194 positive individuals will serorevert [6], it is possible that we have under-  
195 estimated the community-level effect of the intervention. Our study was not  
196 powered to detect changes in seroprevalence in each individual community, and  
197 although the changes were not statistically significant, there were declines in  
198 seroprevalence in every community, consistent with our overall study finding.

199

200 Data on the prevalence and distribution of STHs in the Solomon Islands are  
201 limited. Two previous studies showed that hookworm, whipworm and  
202 roundworm are common [10]. The baseline seroprevalence of *S. stercoralis* in 0-  
203 12-year-olds in the current study was 9.3%, which is broadly similar to  
204 prevalence of other STH species reported in the Solomon Islands [10]. Current  
205 national deworming guidelines for the Solomon Islands are based on MDA with  
206 albendazole, which is likely to have little or no impact on *S. stercoralis*.

207 Integrated strategies combining albendazole with ivermectin may therefore be  
208 beneficial for control of *S. stercoralis* as well as providing enhanced effectiveness  
209 against several STH species and allowing simultaneous control of scabies, which  
210 is highly endemic in the region [3,7]. The current requirement for two doses of  
211 ivermectin, a week apart, for scabies MDA may represent a logistical barrier to  
212 integration as single-dose treatment is effective against *S. stercoralis* [11]. Newer  
213 anti-parasitic drugs such as moxidectin show promise as single-dose treatment  
214 for scabies, strongyloidiasis and other STH [12,13].

215

216 We have demonstrated that *S. stercoralis* is endemic in the Solomon Islands and  
217 added to the limited data demonstrating that ivermectin MDA, here conducted  
218 for the purpose of scabies control, can also reduce *S. stercoralis* seroprevalence.  
219 These data highlight ancillary benefits that can be conferred by NTD control  
220 programmes and suggest that STH programmes in this region may benefit from  
221 the addition of ivermectin alongside albendazole

222

223 **Disclaimer:** The authors alone are responsible for the views expressed in this  
224 article and they do not necessarily represent the views, decisions or policies of  
225 the institutions with which they are affiliated.

226

227

228 **Funding:**

229 The study was funded by a Wellcome Trust Clinical PhD fellowship to MM  
230 (102807). The US CDC paid the laboratory costs. The funders did not have any  
231 role in the design, conduct or analysis of the study.

232

233 **Contributors:**

234 MM wrote the first draft of the paper. CB, KA, EP conducted laboratory work.  
235 MM, HT, CK, JA, RA conducted fieldwork. MM, CB, KA, analysed the data. MM, JD,  
236 JKM, LR, MRM, DM, AWS, DCWM, AS designed and supervised the study. All  
237 authors revised the manuscript.

238

239

240 **Declaration of Interests:**

241 The authors have no competing interests to declare

242

243 **Supplementary Files:**

244 S1 Data – Study Dataset

245 S2 Checklist – Strobe Checklist

246

247

248



249 **References:**

- 250 1. Grove DI. Human strongyloidiasis. *Adv Parasitol* **1996**; 38:251–309.
- 251 2. Krotneva SP, Coffeng LE, Noma M, et al. African Program for Onchocerciasis  
252 Control 1995–2010: Impact of Annual Ivermectin Mass Treatment on Off-  
253 Target Infectious Diseases. *PLoS Negl Trop Dis* **2015**; 9:e0004051.
- 254 3. Romani L, Marks M, Sokana O, et al. Efficacy of mass drug administration  
255 with ivermectin for control of scabies and impetigo, with coadministration  
256 of azithromycin: a single-arm community intervention trial. *Lancet Infect  
257 Dis* **2019**; 19:510–518.
- 258 4. Ravi V, Ramachandran S, Thompson RW, Andersen JF, Neva FA.  
259 Characterization of a recombinant immunodiagnostic antigen (NIE) from  
260 *Strongyloides stercoralis* L3-stage larvae. *Mol Biochem Parasitol* **2002**;  
261 125:73–81.
- 262 5. Buonfrate D, Sequi M, Mejia R, et al. Accuracy of Five Serologic Tests for the  
263 Follow up of *Strongyloides stercoralis* Infection. *PLoS Negl Trop Dis* **2015**;  
264 9:e0003491.
- 265 6. Mitchell T, Lee D, Weinberg M, et al. Impact of Enhanced Health  
266 Interventions for United States–Bound Refugees: Evaluating Best Practices  
267 in Migration Health. *Am J Trop Med Hyg* **2018**; 98:920–928.
- 268 7. Marks M, Toloka H, Baker C, et al. Randomized Trial of Community  
269 Treatment With Azithromycin and Ivermectin Mass Drug Administration for  
270 Control of Scabies and Impetigo. *Clin Infect Dis Off Publ Infect Dis Soc Am*  
271 **2019**; 68:927–933.
- 272 8. Kearns TM, Currie BJ, Cheng AC, et al. *Strongyloides* seroprevalence before  
273 and after an ivermectin mass drug administration in a remote Australian  
274 Aboriginal community. *PLoS Negl Trop Dis* **2017**; 11:e0005607.
- 275 9. Anselmi M, Buonfrate D, Guevara Espinoza A, et al. Mass Administration of  
276 Ivermectin for the Elimination of Onchocerciasis Significantly Reduced and  
277 Maintained Low the Prevalence of *Strongyloides stercoralis* in Esmeraldas,  
278 Ecuador. *PLoS Negl Trop Dis* **2015**; 9:e0004150.
- 279 10. Harrington H, Bradbury R, Taeka J, et al. Prevalence of soil-transmitted  
280 helminths in remote villages in East Kwaio, Solomon Islands. *West Pac  
281 Surveill Response J WPSAR* **2015**; 6:51–58.
- 282 11. Buonfrate D, Salas-Coronas J, Muñoz J, et al. Multiple-dose versus single-  
283 dose ivermectin for *Strongyloides stercoralis* infection (Strong Treat 1 to 4):  
284 a multicentre, open-label, phase 3, randomised controlled superiority trial.  
285 *Lancet Infect Dis* **2019**; 0. Available at:  
286 [https://www.thelancet.com/journals/laninf/article/PIIS1473-](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30289-0/abstract)  
287 [3099\(19\)30289-0/abstract](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30289-0/abstract). Accessed 25 September 2019.

- 288 12. Bernigaud C, Fang F, Fischer K, et al. Preclinical Study of Single-Dose  
289 Moxidectin, a New Oral Treatment for Scabies: Efficacy, Safety, and  
290 Pharmacokinetics Compared to Two-Dose Ivermectin in a Porcine Model.  
291 PLoS Negl Trop Dis **2016**; 10:e0005030.
- 292 13. Barda B, Sayasone S, Phongluxa K, et al. Efficacy of Moxidectin Versus  
293 Ivermectin Against *Strongyloides stercoralis* Infections: A Randomized,  
294 Controlled Noninferiority Trial. Clin Infect Dis **2017**; 65:276–281.
- 295
- 296
- 297

298 **TABLE 1: *Strongyloides stercoralis* seroprevalence in children aged 0–12 before and after ivermectin mass drug administration**

	Community					Total
	1	2	3	4	5	
<b>Baseline seroprevalence % (n/N)</b>	14.3% (19/133)	2.2% (2/90)	11.4% (8/70)	9.0% (13/144)	7.8% (8/102)	9.3% (50/539)
<b>12-month follow-up Seroprevalence % (n/N)</b>	5.2% (6/110)	2.1% (2/94)	6.9% (5/72)	6.7% (7/105)	4.9% (3/61)	5.1% (23/448)
<b>Absolute reduction</b>	9.1%	0.1%	4.5%	2.3%	2.9%	4.2%*
<b>Relative reduction</b>	36.4%	4.5%	60.5%	25.6%	37.2%	45.2%*
<b>Baseline scabies prevalence</b>	10.1%	12.2%	9.4%	7.1%	13.9%	10.5%

299 \* p < 0.05